Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

ipharmaservices
Jul 10, 2023
0 min read

Recent Posts

European Commission grants approval to Sanofi's Wayrilz for refractory immune thrombocytopenia | iPharmaCenter

European Commission grants approval to Sanofi's Wayrilz (rilzabrutinib), marking the first Bruton's tyrosine kinase (BTK) inhibitor for adult patients with refractory immune thrombocytopenia (ITP). Wa

Johnson & Johnson Secures European Commission Approval for IMAAVY (Nipocalimab) to Treat Generalised Myasthenia Gravis

The European Commission has granted Marketing Authorisation to Johnson & Johnson for IMAAVY (nipocalimab), a novel FcRn-blocking antibody therapy designed to help people living with generalised myasth

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

Switzerland’s new understanding with the US goes beyond a minor tariff tweak and directly touches the country’s role as a pharma and med‑tech hub. Under a November memorandum of understanding, Washing

iPharmaCenter

ipharmacenter Consulting services

Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

Recent Posts

Comments